Ex situ liver perfusion: Organ preservation into the future

Mariusz Bral; Boris Gala-Lopez; David L. Bigam; Darren H. Freed; A. M.James Shapiro

doi:10.1016/j.trre.2018.03.002

Ex situ liver perfusion: Organ preservation into the future

Mariusz Bral, Boris Gala-Lopez, David L. Bigam, Darren H. Freed, A. M.James Shapiro

Research output: Contribution to journal › Review article › peer-review

8 Citations (Scopus)

Abstract

In recent years, remarkable progress has occurred in the development of technologies to support ex situ liver perfusion. Building upon extensive preclinical studies in large animal models, pilot and randomized clinical trials have been initiated, and preliminary outcomes suggest more optimal protection of both standard and extended criteria liver grafts. There currently exists an incredible opportunity and need to further refine this technology, determine appropriate viability measures to predict usable liver grafts, and to explore potent protective additive strategies to further optimize the quality of extended criteria organs. These findings will have major bearing in expanding the limited liver donor pool, and may save lives where up to a quarter of listed patients die on wait-lists. Herein we offer a brief overview of the history and current status of ex situ liver perfusion, and discuss future directions that will likely have major impact on the practice of clinical liver transplantation.

Original language	English
Pages (from-to)	132-141
Number of pages	10
Journal	Transplantation Reviews
Volume	32
Issue number	3
DOIs	https://doi.org/10.1016/j.trre.2018.03.002
Publication status	Published - Jul 2018
Externally published	Yes

Bibliographical note

Funding Information:
Funding: MB is the recipient of the American Society of Transplant Surgeons (ASTS) 2015 Scientist Scholarship. AMJS holds a Canada Research Chair in Transplantation Surgery and Regenerative Medicine, and a Senior Clinical Scholarship from Alberta Innovates Healthcare Solutions. Funding from the University Hospital Foundation at the University of Alberta is gratefully acknowledged. Funding from Astellas Pharma Canada is gratefully acknowledged.

Publisher Copyright:
© 2018 Elsevier Inc.

ASJC Scopus Subject Areas

Transplantation

Access to Document

10.1016/j.trre.2018.03.002

Cite this

@article{9020c8c57ccb47408240bbb165813ac6,

title = "Ex situ liver perfusion: Organ preservation into the future",

abstract = "In recent years, remarkable progress has occurred in the development of technologies to support ex situ liver perfusion. Building upon extensive preclinical studies in large animal models, pilot and randomized clinical trials have been initiated, and preliminary outcomes suggest more optimal protection of both standard and extended criteria liver grafts. There currently exists an incredible opportunity and need to further refine this technology, determine appropriate viability measures to predict usable liver grafts, and to explore potent protective additive strategies to further optimize the quality of extended criteria organs. These findings will have major bearing in expanding the limited liver donor pool, and may save lives where up to a quarter of listed patients die on wait-lists. Herein we offer a brief overview of the history and current status of ex situ liver perfusion, and discuss future directions that will likely have major impact on the practice of clinical liver transplantation.",

author = "Mariusz Bral and Boris Gala-Lopez and Bigam, {David L.} and Freed, {Darren H.} and Shapiro, {A. M.James}",

note = "Funding Information: Funding: MB is the recipient of the American Society of Transplant Surgeons (ASTS) 2015 Scientist Scholarship. AMJS holds a Canada Research Chair in Transplantation Surgery and Regenerative Medicine, and a Senior Clinical Scholarship from Alberta Innovates Healthcare Solutions. Funding from the University Hospital Foundation at the University of Alberta is gratefully acknowledged. Funding from Astellas Pharma Canada is gratefully acknowledged. Publisher Copyright: {\textcopyright} 2018 Elsevier Inc.",

year = "2018",

month = jul,

doi = "10.1016/j.trre.2018.03.002",

language = "English",

volume = "32",

pages = "132--141",

journal = "Transplantation Reviews",

issn = "0955-470X",

publisher = "W.B. Saunders Ltd",

number = "3",

}

TY - JOUR

T1 - Ex situ liver perfusion

T2 - Organ preservation into the future

AU - Bral, Mariusz

AU - Gala-Lopez, Boris

AU - Bigam, David L.

AU - Freed, Darren H.

AU - Shapiro, A. M.James

N1 - Funding Information: Funding: MB is the recipient of the American Society of Transplant Surgeons (ASTS) 2015 Scientist Scholarship. AMJS holds a Canada Research Chair in Transplantation Surgery and Regenerative Medicine, and a Senior Clinical Scholarship from Alberta Innovates Healthcare Solutions. Funding from the University Hospital Foundation at the University of Alberta is gratefully acknowledged. Funding from Astellas Pharma Canada is gratefully acknowledged. Publisher Copyright: © 2018 Elsevier Inc.

PY - 2018/7

Y1 - 2018/7

N2 - In recent years, remarkable progress has occurred in the development of technologies to support ex situ liver perfusion. Building upon extensive preclinical studies in large animal models, pilot and randomized clinical trials have been initiated, and preliminary outcomes suggest more optimal protection of both standard and extended criteria liver grafts. There currently exists an incredible opportunity and need to further refine this technology, determine appropriate viability measures to predict usable liver grafts, and to explore potent protective additive strategies to further optimize the quality of extended criteria organs. These findings will have major bearing in expanding the limited liver donor pool, and may save lives where up to a quarter of listed patients die on wait-lists. Herein we offer a brief overview of the history and current status of ex situ liver perfusion, and discuss future directions that will likely have major impact on the practice of clinical liver transplantation.

AB - In recent years, remarkable progress has occurred in the development of technologies to support ex situ liver perfusion. Building upon extensive preclinical studies in large animal models, pilot and randomized clinical trials have been initiated, and preliminary outcomes suggest more optimal protection of both standard and extended criteria liver grafts. There currently exists an incredible opportunity and need to further refine this technology, determine appropriate viability measures to predict usable liver grafts, and to explore potent protective additive strategies to further optimize the quality of extended criteria organs. These findings will have major bearing in expanding the limited liver donor pool, and may save lives where up to a quarter of listed patients die on wait-lists. Herein we offer a brief overview of the history and current status of ex situ liver perfusion, and discuss future directions that will likely have major impact on the practice of clinical liver transplantation.

UR - http://www.scopus.com/inward/record.url?scp=85046121009&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85046121009&partnerID=8YFLogxK

U2 - 10.1016/j.trre.2018.03.002

DO - 10.1016/j.trre.2018.03.002

M3 - Review article

C2 - 29691119

AN - SCOPUS:85046121009

SN - 0955-470X

VL - 32

SP - 132

EP - 141

JO - Transplantation Reviews

JF - Transplantation Reviews

IS - 3

ER -

Ex situ liver perfusion: Organ preservation into the future

Abstract

Bibliographical note

ASJC Scopus Subject Areas

Access to Document

Other files and links

Fingerprint

Cite this